Literature DB >> 33661409

Peak strain dispersion within the left ventricle detected by two-dimensional speckle tracking in patients with uncomplicated systemic lupus erythematosus.

Chunmei Li1, Kun Li2, Miao Yuan3, Wenjuan Bai1, Li Rao4.   

Abstract

Systemic lupus erythematosus (SLE) often leads to various cardiovascular diseases. We aimed to investigate the value of peak strain dispersion (PSD) in evaluating left ventricular dysfunction in patients with uncomplicated SLE. Eighty-seven female SLE patients and fifty-nine healthy female controls were recruited. The SLE patients were divided into inactive disease (SLE disease activity index (SLEDAI) ≤ 4; n = 48) and active disease (SLEDAI ≥ 5; n = 39) subgroups. Traditional echocardiography and two-dimensional speckle-tracking echocardiography were performed using a GE VividE9 ultrasound diagnostic system and an advanced quantitative analysis EchoPAC workstation (version 201), respectively. The global longitudinal strain (GLS) in the SLE with SLEDAI ≤ 4 group was comparable to that in the control group (- 19.89% vs - 20.7%; P = 0.061). However, GLS was obviously damaged in the SLE with SLEDAI ≥ 5 group compared with that in the control group (- 19.07% vs - 20.7%; P < 0.001). PSD impairment was observed in the SLE with SLEDAI ≤ 4 group (33.83 ms vs 31.44 ms; P = 0.012) and SLE with SLEDAI ≥ 5 groups (52.31 ms vs 31.44 ms; P < 0.001), but the largest difference was observed in the active disease group. Linear regression analysis showed that PSD was moderately correlated with the SLEDAI (r = 0.535; P < 0.001) in SLE patients with SLEDAI ≤ 4 and showed the best correlation with the SLEDAI (r = 0.646; P < 0.001) in the SLE patients with SLEDAI ≥ 5. A correlation between GLS and the SLEDAI (r = 0.359; P = 0.025) was found in the active disease group but not in the inactive disease group (r = 0.253; P = 0.082). PSD is more comprehensive and accurate for evaluating left ventricular subclinical dysfunction in SLE patients. In inactive SLE patients, PSD is a more sensitive index to evaluate early systolic dysfunction of the left ventricle. GLS may be a more vulnerable indicator of early left ventricular cardiac dysfunction in active SLE patients. Controlling disease activity may reduce the events of cardiac dysfunction.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Global longitudinal strain; Peak strain dispersion; Systemic Lupus Erythematosus Disease Activity Index; Systemic lupus erythematosus; Two-dimensional speckle-tracking echocardiography

Year:  2021        PMID: 33661409     DOI: 10.1007/s10554-021-02201-7

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  40 in total

1.  Lymphocyte populations and cytokine concentrations in pericardial fluid from a systemic lupus erythematosus patient with cardiac tamponade.

Authors:  L M Vilá; J R Rivera del Río; Z Ríos; E Rivera
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

Review 2.  Therapy insight: systemic lupus erythematosus as a risk factor for cardiovascular disease.

Authors:  Sahena Haque; Ian N Bruce
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2005-08

3.  Cardiovascular event in systemic lupus erythematosus in northern Sweden: incidence and predictors in a 7-year follow-up study.

Authors:  C Bengtsson; M-L Ohman; O Nived; S Rantapää Dahlqvist
Journal:  Lupus       Date:  2011-11-07       Impact factor: 2.911

4.  Comparison of non-invasive assessment of arrhythmias, conduction disturbances and cardiac autonomic tone in systemic sclerosis and systemic lupus erythematosus.

Authors:  Piotr Bienias; Michał Ciurzyński; Bartłomiej Kisiel; Anna Chrzanowska; Katarzyna Ciesielska; Maria Siwicka; Agnieszka Kalińska-Bienias; Marek Saracyn; Monika Lisicka; Joanna Radochońska; Piotr Pruszczyk
Journal:  Rheumatol Int       Date:  2018-11-12       Impact factor: 2.631

Review 5.  Cardiac involvement in systemic lupus erythematosus.

Authors:  A Doria; L Iaccarino; P Sarzi-Puttini; F Atzeni; M Turriel; M Petri
Journal:  Lupus       Date:  2005       Impact factor: 2.911

6.  Cutaneous lupus erythematosus and systemic lupus erythematosus are associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

Authors:  J Halskou Hesselvig; O Ahlehoff; L Dreyer; G Gislason; K Kofoed
Journal:  Lupus       Date:  2016-05-27       Impact factor: 2.911

7.  Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus.

Authors:  W H Leung; K L Wong; C P Lau; C K Wong; H W Liu
Journal:  Am J Med       Date:  1990-10       Impact factor: 4.965

8.  Epidemiology and survival of systemic lupus erythematosus in Hong Kong Chinese.

Authors:  C C Mok
Journal:  Lupus       Date:  2010-12-10       Impact factor: 2.911

9.  Measuring Disease Activity and Damage with Validated Metrics: A Systematic Review on Mortality and Damage in Systemic Lupus Erythematosus.

Authors:  Stephanie O Keeling; Ben Vandermeer; Jorge Medina; Trish Chatterley; Tatiana Nevskaya; Janet Pope; Zainab Alaburubalnabi; Asvina Bissonauth; Zahi Touma
Journal:  J Rheumatol       Date:  2018-08-15       Impact factor: 4.666

10.  Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort.

Authors:  Christie M Bartels; Kevin A Buhr; Jerry W Goldberg; Carolyn L Bell; Maja Visekruna; Swapna Nekkanti; Robert T Greenlee
Journal:  J Rheumatol       Date:  2014-02-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.